Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised placebo-controlled clinical trial
Version 2 2024-05-30, 15:37Version 2 2024-05-30, 15:37
Version 1 2014-10-28, 09:21Version 1 2014-10-28, 09:21
journal contribution
posted on 2024-05-30, 15:37 authored by Michael BerkMichael Berk, CS Gama, S Sundram, H Hustig, L Koopowitz, R D'Souza, H Malloy, C Rowland, A Monkhouse, F Bole, S Sathiyamoorthy, D Piskulic, Seetal DoddSeetal DoddAbstractObjectiveSchizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, particularly in negative symptoms. This study investigates the efficacy of adding mirtazapine to treatment as usual to alleviate the negative symptoms of schizophrenia.MethodsIn a 6 week, double‐blind clinical trial, participants with a diagnosis of schizophrenia and currently being treated with atypical antipsychotic medication were randomised to adjunctive treatment with mirtazapine (30 mg/day) or placebo. The primary outcome measure was improvement in the Positive and Negative Syndrome Scale (PANSS). Measures of cognition, collected at baseline and week 6 only, were analysed using an Analysis of Covariance (ANCOVA) model. All other outcome measures were analysed using a linear mixed model.ResultsForty participants were recruited to the study with equal numbers randomised to each treatment arm. There was no significant difference between mirtazapine and placebo treated participants for improvement in PANSS scores or any of the secondary outcome measures at any stage during the 6‐week trial.ConclusionsThis trial does not confirm previous research supporting the use of mirtazapine adjunctive to atypical antipsychotic treatment for schizophrenia. Copyright © 2009 John Wiley & Sons, Ltd.
History
Journal
Human PsychopharmacologyVolume
24Pagination
233-238Location
EnglandPublisher DOI
ISSN
0885-6222eISSN
1099-1077Language
EnglishPublication classification
C1.1 Refereed article in a scholarly journalCopyright notice
2009, John Wiley & SonsIssue
3Publisher
WILEYPublication URL
Usage metrics
Categories
No categories selectedKeywords
Science & TechnologySocial SciencesLife Sciences & BiomedicineClinical NeurologyPharmacology & PharmacyPsychiatryPsychologyNeurosciences & Neurologymirtazapineschizophrenianegative symptomsantipsychoticsclinical trialIMPROVES NEGATIVE SYMPTOMSRESISTANT SCHIZOPHRENIAINVERSE AGONISTAUGMENTATIONCLOZAPINEMIANSERINHALOPERIDOLSERTRALINEEFFICACY119999 Medical and Health Sciences not elsewhere classified970111 Expanding Knowledge in the Medical and Health Sciences
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC